2021年11月17〜18日|バーチャル
ワクチン世界アジア会議
シンガポール
参加する ワクチン世界アジア会議2021！
800+
知名度の高い参加者
200+
主要なステークホルダー企業
50+
エキスパートスピーカー
20+
ネットワーキングの時間
の 概念
医療費の増加、ワクチン技術の進歩、予防ワクチン、特に新しいCOVID-19ワクチンの需要の高まりにより、アジア太平洋地域の予防ワクチン市場は年間12.89%増加し、2020年までの総市場上限は$972億になります。および2026。
コロナウイルス感染症は最近、世界中の何百万もの人々に感染しています。特定の地域では、地域社会の感染により、世界的な死傷者が増加しています。現在、ビッグファーマとバイオファーマはCOVID-19ワクチンの研究開発に力を注いでいます。 COVID-19のパンデミック状況は前例のない需要を生み出し、企業は臨床試験期間を短縮し、生産効率を高めるための政府の支援と技術の進歩により、研究開発活動に多額の投資を行っています。市場の成長見通しは、高まる需要を満たすためのワクチン製造施設の拡張によって強化されます。
ワクチン世界アジア会議2021は、グローバルパートナーと地域の利害関係者を集めてパートナーシップの機会を活用し、最新の技術進歩と先駆的な科学革新について学ぶ、アジアで唯一のワクチンに焦点を当てたプラットフォームになります。このイベントは、Big Pharmas、International Biopharma、Asian Biopharma、Academic＆Research Institutes、Regulatory Authority、NGO、Solution Providers、Technocratsのホスト役を務めます。
今回のVaccineWorld Asiaでは、Asia-Pacific Vaccine ExcellenceAwardsと同じ場所に配置されています。アジアのワクチン事業があなたにとって重要であるならば、ワクチン世界アジア会議2021はあるべき場所です！
会議 議題
Vaccine World Asia Congressは、シンガポールで唯一のワクチンに焦点を当てたプラットフォームであり、グローバルパートナーと地域の利害関係者を結集して、パートナーシップの機会を活用し、最新の技術進歩と先駆的な科学革新について学びます。このイベントでは、BIGファーマ、インターナショナルバイオファーマ、アジアバイオファーマ、学術研究機関、規制当局、NGO、ソリューションプロバイダー、テクノクラートが主催します。アジアのワクチン事業が重要な場合は、Vaccine World Asia2021が最適です。
今すぐ登録！
2021 スピーカー
Jerome H. Kim 国際ワクチン研究所
M.D, Director General国際ワクチン研究所韓国 Jerome Kim, M.D., is an international expert on the evaluation and development of vaccines and is the Director-General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective, and affordable vaccines for Global Health. His depth and breadth of scientific experience span basic research through advanced clinical development. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI is working on several different vaccines against COVID-19, including the clinical testing of Inovio’s DNA vaccine at Seoul National University Hospital and Genexine’s COVID-19 vaccine at Severance Hospital.
Dr. Kim was Principal Deputy and Chief, Laboratory of Molecular Virology and Pathogenesis in the U.S. Military HIV Research Program (MHRP) and also served as the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Materiel Development Activity, Fort Detrick, MD. He led the Army's Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination.
Dr. Kim has authored over 300 publications and received the John Maher Award for Research Excellence from the Uniformed Services University of the Health Sciences in 2013 and the Department of the Army R&D Award for Technical Excellence (2013). Dr. Kim is also an Adjunct Professor of Medicine at the Uniformed Services University of the Health Sciences and at Yonsei University Graduate School of Public Health and a Fellow of the American College of Physicians and the Infectious Diseases Society of America.
He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology, and received his M.D. from Yale University School of Medicine.
Zhong Kai Shi Yisheng Biopharma
Ph.D, Chief Medical OfficerYisheng Biopharma中国Dr. Shi brings over 20 years of experience in global product development. Prior to joining Yisheng, Dr. Shi led global product development as Director of Clinical Development at the vaccine development organization Aeras. Before Aeras, Dr. Shi was Director of Vaccine Development at Altimmune. He received his M.D. from Beijing University and earned an MBA from the University of Alabama at Birmingham.
Han S Kierstead AIVITA Biomedical
最高経営責任者（CEOAIVITA Biomedical米国 Dr. Keirstead is an internationally known stem cell expert and serial entrepreneur that has led therapy development for cancer, immune disorders, motor neuron diseases, spinal cord injury, and retinal diseases. He is the Chairman and CEO of AIVITA Biomedical. He has founded 4 successful biotechnology companies, each returning significant value to investors and treatments to patients. He holds Board positions in several prominent biotechnology companies. He was a full Professor at the University of California, Irvine where he founded, directed, and erected a building for the UCI Stem Cell Research Center. He was a founding advisor of the California Stem Cell Initiative that resulted in a $3 billion stem cell fund (CIRM). He has been a long-time advisor to several governments on biomedical policy. Dr. Keirstead received his Ph.D. in neuroscience from the University of British Columbia, Canada, receiving the Cameron Award for outstanding Ph.D. thesis in the country. He received the distinct honor of election as Senate Member of the University of Cambridge and Fellow of the Governing Body of Downing College and was the youngest member to have been elected to those positions.
Raches Ella Bharat Biotech
プロジェクトリーダー：SARS-CoV-2ワクチンBharat Biotechインド
Mark Newman GeoVax
Chief Scientific Officer, GeoVax, USA GeoVax米国 Dr. Newman has more than 30 years of experience in the biotechnology sector serving in senior management roles at GeoVax (Atlanta, GA), PaxVax (San Diego, CA), Pharmexa (Horsholm, Denmark), Epimmune (San Diego, CA), Vaxcel (Atlanta, GA), Apollon (Philadelphia, PA) and Cambridge Biotech (Boston, MA) where he directed research, development and early-stage clinical testing of protein, peptide, plasmid DNA and viral vectored vaccines and multiple vaccine adjuvants. He participated with or directed teams responsible for the transition of 10 vaccine or vaccine-related products from the research stage to Phase 1 and 2 clinical testings. He also served as the primary scientific director for multiple corporate teams that completed Due Diligence reviews, technology assessments, and intellectual property reviews, and portfolio management to support strategic planning, technology in-licensing, and out-licensing, corporate partnering, and mergers and acquisitions.
Dr. Newman has co-authored more than 100 scientific papers, reviews, and book chapters during his professional career. He is a named co-inventor on multiple issued US and PCT patents, all related to vaccine technologies. He served as the Principal Investigator on multiple USA government and foundation grants and contracts and has served as a grant and contract review expert for 20 years for the National Institutes of Health.
Dr. Newman is a graduate of the Ohio State University (B.Sc. and M.Sc.) and received his Ph.D. in Immunology from the John Curtin School of Medical Research, the Australian National University (Canberra, Australia). He completed four years of post-doctoral training at Cornell University and the Uniformed Services University of Health Sciences under contract with the National Cancer Institute, National Institutes of Health. He also served four years as a full-time member of the Louisiana State University faculty at the School of Veterinary Medicine prior to joining the biotechnology industry in 1989.
Samir Desai Cadila Healthcare Limited（Zydus Cadila）
President & Head of BU Biologics Cadila Healthcare Limited（Zydus Cadila）インド Industry experience of close to 3 decades having handled sales, training, brand management, marketing and commercial operations. Current role includes commercial operations for vaccines & biologics and small molecules across specialties & geographies, Business Development, In & Out licensing, portfolio planning. Extensively worked in the area of maternal health related public policy advocacy, improving access to HCV medicines etc. Handled vaccines since 2 decades.
Randall Hyer Moderna
MD, PhD, MPH, Senior Vice President, Global Medical Affairs, Moderna, USA Moderna米国 Dr. Hyer has over three decades of experience in medicine and public health in both the public and private sectors. After graduating with distinction from the US Naval Academy, he studied at Duke Medical School and then earned a Ph.D. in molecular biology from Oxford University. He then spent 13 months on the “ice” in Antarctica as the Station Physician for the winter. Dr. Hyer then shifted to public health and vaccines, serving four years at the World Health Organization as a medical officer responding to outbreaks and emergencies including anthrax, Ebola, SARS, avian influenza, as well as tsunamis and earthquakes. In response to the need for effective communication, Randy co-authored a popular WHO handbook on risk and crisis communication during public health emergencies. In industry, Randy’s experience covers vaccines, biologics, biosimilars, and small molecule development. He was pivotal to the 2017 approval of a two-dose adult hepatitis B vaccine (HEPLISAV-B), the first FDA-approved vaccine with a truly novel adjuvant. Beyond development, his responsibilities have included directing vaccine and pharmaceutical safety programs, overseeing vaccine clinical operations and biometrics functions, engaging medical scientists and policy-makers, and managing crises. Randy’s perspectives and contributions span his residing in eight and traveling to 100 plus countries in diverse roles across the public and private sectors.
Joseph Payne Arcturus Therapeutics
社長兼CEOArcturus Therapeutics米国Joseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.
Alexandre, Le Vert Osivax
最高経営責任者（CEOOsivaxフランスAlexandre has broad experience in healthcare ranging from research and development to commercialization of vaccines and therapeutics. He is an experienced entrepreneur in biotech and innovation. Alexandre is a Board Member of several biotech companies in France and in the US.
Ingrid Kromann CEPI
Head of CMCCEPIイギリス Ingrid Kromann started 01 March 2020 as Head of CMC, CEPI, UK. The CEPI CMC team is facilitating the vaccine developers in process development and scale-up activities.
Ingrid has a background as a chemical engineer. She has more than 25 years experience of working with vaccines through her employment at Statens Serum Institut, Denmark.
For the last 16 years, Ingrid led the Vaccine development department at Statens Serum Institut and has developed more than 10 different vaccines from research to clinical trials, mostly within Tuberculosis, Polio, and Chlamydia.
Rong Xu Clover Biopharmaceuticals
Senior Vice President, re-Clinical R&D (Vaccine)Clover Biopharmaceuticals中国
Kevin Wang, Ph.D CC-Pharming Ltd.
Chairman/CSOCC-Pharming Ltd.中国
Kiat Ruxrungtham, MD Department of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC)
Professor of MedicineDepartment of Medicine Chulalongkorn University; and Scientific Chair of the Chula Vaccine Research Center (ChulaVRC) Kiat Ruxrungtham, M.D, Scientific Mentor & Founder, Chula VRC & As Scientific Mentor & Founder of Chula VRC, Kiat Ruxrungtham conducts vaccine research work and gathering professors and researchers interested in the research and development of vaccines into Center of Excellence in Vaccine Research and Development. He spent more than 30 years exploring HIV treatment strategies, HIV T cell immunology, vaccine development (including dengue, HIV, and house dust mite (HDM) vaccine); and strategies to improve DNA vaccine immunogenicity. He has supervised and lead Chula VRC’s effect to rapidly advance the promising HDM vaccine candidates from the lab bench to clinical trial.
Ruxrungtham holds a Professor of Medicine from the Department of Medicine, Chulalongkorn University. He is providing teaching and patient care at the King Chulalongkorn Memorial Hospital and is mentoring junior researchers on the vaccine, immunology research, and also on clinical trials. He currently is a vice president for research and innovation, Chulalongkorn University.
He has published more than 230 peer review papers on HIV, immunology, and allergy. He is a faculty member of the faculty 1000 of Medicine, a chief editor of Asia Pacific J of Allergy, and an editorial board member of Immunology, ImmunoTargets and Therapy, Asian Biomedicine, and the Scientific Report. He is also a reviewer for > 9 journals.
ラジェンドラ・クマール・スリ DCVMN
最高経営責任者（CEODCVMNRajinder Kumar Suriは、2021年1月15日にCEOとしてDCVMN（Developing Countries Vaccine Manufacturers Network）に参加しました。それ以前は、Panacea BiotecLtdの最高経営責任者であるBiologicalsの帽子をかぶっていました。Rajinderは40年以上の医薬品および生物製剤の豊富な経験があります。サノフィパスツールのインド子会社の取締役会での4年間を含む、トップマネジメントレベルでの24年以上の経験のうち、インドおよび国際市場の製品。残りの19年間は製薬会社で、そのうち16年間はルパンでした。スリ氏は、アレテビジネスアドバイザーのCEO兼シニアアドバイザーとして3年以上のコンサルティング経験を持っています。 Rajinderは、2013年10月から2017年6月までDCVMNを代表するGAVI理事会の諮問機関であるメンバーポリシーおよび計画委員会（PPC）であり、GAVI供給および調達戦略運営委員会のメンバーでもあります。彼は、保健省、インド政府、国連機関、およびWHO、ユニセフ、ビル＆メリンダゲイツ財団、クリントンヘルスアクセスイニシアチブなどの他のグローバル組織との交渉と交流において主導的な役割を果たしてきました。 Rajinderは、2014年10月から2016年までの2年間、DCVMNの元メンバー実行委員会および副社長でもあります。
Vasan K Sambandamurthy India Alliance
最高経営責任者（CEOIndia Allianceインド Vasan Sambandamurthy joined the DBT/Wellcome Trust India Alliance in October 2020 with over 20 years of professional experience in vaccine discovery and drug development. He has previously worked for major global corporations like Novartis, AstraZeneca, and Biocon. At these organizations, Vasan has held senior leadership positions, provided strategic directions, and orchestrated major business operations to develop affordable medicines across multiple therapeutic areas including oncology, diabetes, infectious diseases (specifically in tuberculosis and malaria), and inflammation.
Vasan completed his post-doctoral training as a Howard Hughes Medical Institute (HHMI) fellow at the Albert Einstein College of Medicine in New York. He gained his Ph.D. from the Tuberculosis Research Centre (Indian Council of Medical Research) in Chennai and completed his post-graduate degree in Medical Microbiology from the Christian Medical College and Hospital in Vellore. He went on to leverage his academic training and real-world experience in managing large Research & Development portfolios, interdisciplinary and cross-functional global teams, regulatory submissions, and global alliances to advance diverse classes of molecules into clinical development.
In his spare time, Vasan is a prolific long-distance runner, avid trekker, and classical music enthusiast.
ファーシャッドギラクー博士 COVAXXとVAXXINITY
最高科学責任者COVAXXとVAXXINITY米国
Elena Smith サノフィパスツール
Deputy Director, Analytical Expert - Quality (Protein Sciences Site)サノフィパスツール米国
Etleva Kadilli ユニセフ
供給部長ユニセフコペンハーゲンデンマークEtleva（Eva）Kadilliは、デンマークのコペンハーゲンに拠点を置くユニセフのサプライ部門のディレクターであり、年間支出が38億米ドルを超えるユニセフのグローバルサプライチェーン機能を監督しています。この職務において、彼女は、直接のユニセフプログラムを通じて、また各国政府やパートナーと協力して、子供たちに不可欠で緊急の物資を効果的、効率的、かつ倫理的に提供することを主導しています。人道的危機に対するユニセフの供給対応の管理を担当するカディリ氏は、現在、COVID-19パンデミックに対する組織の戦略的調達およびロジスティクス緊急対応を主導しています。この職務において、彼女は国連COVIDサプライチェーンタスクフォースでユニセフを代表し、国連調達改革に関する省庁間の関与や、ガビ委員会の代替メンバーであるワクチン同盟など、他の多くのグローバルフォーラムでも組織を代表しています。 Kadilli氏は、Gaviの監査および財務委員会、および市場に敏感な意思決定委員会にも参加しています。ユニセフのスタッフメンバーであるカディリ氏は、本部および現場レベルで、またアルバニア、コンゴ民主共和国（DRC）、ガンビア、ソマリアなどの開発および緊急事態において、いくつかの役割を果たしてきました。 。カディリ氏は2011年からユニセフのサプライ部門に勤務しており、以前はサプライチェーンの副所長を務め、契約の方針と手順、品質保証、グローバルロジスティクス業務、緊急対応を担当するチームを監督していました。彼女の他の役割には、調達の監視とコンプライアンスを担当する契約責任者が含まれています。 2014年から2016年のエボラ出血熱の発生時を含め、MNCHおよびHIV / AIDSプログラムを支援する医療技術供給の契約マネージャーおよび医療ユニットチームリーダー。
チェン・ユジアオ 北京CCファーミング
共同創設者兼エグゼクティブVP北京CCファーミング中国
Dr. Gaurab Sircar Visva Bharati University, Santiniketan,
教授Visva Bharati University, Santiniketan,インドCurrently working as a DBT/Wellcome Trust India Alliance Early Career Fellow at Visva-Bharati, Santiniketan. I obtained my MSc in Botany from Calcutta University followed by Ph.D. from Bose Institute, Kolkata. Following 3 years of postdoctoral training from Bose Institute and then from Harvard Medical School, Boston, MA, USA, I joined Visva-Bharati as an ECF. For the last 10 years, I have been pursuing research in the field of ‘Molecular Allergology and Clinical Immunology’ with an aim to develop molecular diagnostics and immunotherapeutics for allergic diseases. I am currently working on designing recombinant vaccines for patient-tailored immunotherapy to treat allergic asthma triggered by Aspergillus fumigatus, a ubiquitously present pathogenic mold.
Sanjeev Kumar, Ph.D International Centre for Genetic Engineering and Biotechnology (ICGEB),
DBT/Wellcome Trust India Alliance Early Career Fellow, ICGEB-Emory Vaccine ProgramInternational Centre for Genetic Engineering and Biotechnology (ICGEB), インドHe is presently working as a DBT-Wellcome Trust India Alliance Early Career Fellow at ICGEB-Emory Vaccine Program, ICGEB, Delhi, India. His present work involves studying the humoral antibody response against DENV and SARS-CoV-2 infections; isolation and characterization of human monoclonal neutralizing antibodies for viral infections and engineered viral antigen-based vaccine design using Reverse Vaccinology 2.0 approach. In the past as a part of his Ph.D. at AIIMS, New Delhi, India under the supervision of Prof. Kalpana Luthra, he worked on isolation and characterization of human anti-HIV-1 monoclonal antibodies using high-throughput antigen specific single B cell sorting technology. He has designed a protein based HIV-1C immunogen as a part of his EMBO short-term fellowship, Rogier Sanders Lab, AMC, Amsterdam. Further, he gained expertise in 10x genomics for single B cell-based Next-gen sequencing and BCR repertoire RNA-seq and data analysis from Dennis Burton Lab, The Scripps Research Institute, San Diego, CA, USA as a part of HIV Research Trust Scholarship, UK. In his master’s thesis work, he made human cross-neutralizing anti-HIV-1 scFvs against the CD4bs from a phage library constructed from HIV-1 clade-C infected Indian pediatric donors.
Ajoy Chakrabarti ビル＆メリンダゲイツ財団
Portfolio And Platform Leadビル＆メリンダゲイツ財団米国Dr. Chakrabarti has over 25 years of diverse product development experience in both pharmaceutical and biotechnology companies. He joined the Gates Foundation in 2016, working across multiple polio vaccine programs to provide strategic guidance and product development expertise as part of the global effort to eradicate polio. Prior to joining the Foundation, he spent eight years leading cross-functional development teams working on anthrax therapeutics and vaccines, as well as nerve agent antidotes at Emergent BioSolutions
マシュー・ダウンハム CEPI
持続可能な製造リードCEPIイギリスダウンハム博士は、ロンドンサウスバンクポリテクニック（英国）で産業生物学の理学士号（優等）を取得しました。これには、ベーリンガーマンハイム（ドイツ）への配置も含まれます。その後、博士号を取得しました。生物化学工学（バーミンガム大学、英国）、ポスドク研究員-生体分子科学（リバプールジョンムーア大学、英国）、および高等教育の大学院修了証書（ボルトン研究所、英国）。彼は1997年にバイオ医薬品業界に加わり、Protherics（UK）、Bavarian Nordic＆Morphosys（DE）、Novartis Vaccines＆Diagnostics（IT）、AstraZeneca（UK）で働いてきました。ダウンハム博士は、感染症、高血圧、炎症、および腫瘍学の適応症に対するワクチン、抗体、または酵素療法の前臨床および初期の臨床開発に取り組みました。彼はヨーロッパの登録毒物学者でした（2010-18）。 Vaccines Europe Influenzaワーキンググループ（2017-20）の議長。国際製薬団体連合会インフルエンザワクチン供給タスクフォース（2017-20）の会計係。生物多様性に関するIFPMA条約ワーキンググループ（2018-20）副議長。ダウンハム博士はまた、29の出版物/要約と3つの国際特許を共同執筆し、2021年1月に、持続可能な製造リーダーとして感染症対策イノベーション連合（UK）に参加しました。重要な関連情報：BSc Hons Industrial Biology（London South Bank Polytechnic、UK＆Boehringer Mannheim、DE）、Ph.D。生化学工学（バーミンガム大学、英国）、PGCE（ボルトン研究所、英国）、博士課程後の研究フェローシップ–生体分子科学（リバプールジョンムーア大学、英国）およびEU登録毒物学者（英国王立生物学会、2010-'18） 25年の国際的な生物医薬品産業：ベーリンガーマンハイム（DE）、プロテリックス（UK）、バイエルンノルディック＆モルフォシス（DE）、ノバルティスワクチン＆ダイアグノスティックス（IT）、アストラゼネカ（UK）。
Nguyen Tuyet Nga 道
Vietnam Country Director, PATH, Vietnam 道ベトナム Dr. Nguyen Tuyet Nga is PATH’s country director for Vietnam. She leads a broad portfolio of projects that focus on vaccines and immunization; infectious diseases including HIV, tuberculosis, and malaria; non-communicable diseases including heart disease and diabetes; infection prevention and control and antimicrobial resistance; and health systems strengthening via digital tools, improved data and data use culture, and strengthened primary health care. Nga also leads on regional programs that provide support to health systems and providers in Cambodia, Laos, and other countries in the region.
Nga is a medical doctor with particular experience in epidemiology, infectious disease control, vaccine development, and immunization programs. She has more than 25 years of experience in vaccine development and production (including clinical trials and licensing), immunization programming, infectious disease control including for HIV and tuberculosis, and in leading teams that promote the use of digital solutions and data for more effective, efficient, and resilient health systems.
Nga has been working with PATH since 2009, working as a technical advisor and in program management roles across PATH’s vaccines and immunization, tuberculosis, and digital solutions and data portfolios. Nga became the Vietnam Program Team Leader in 2014, the Deputy Country Director in 2018, and the Vietnam Country Director in 2019.
Before joining PATH, Nga was the head of the Research and Development Department at VABIOTECH, one of the largest vaccine companies in Vietnam, and worked as a researcher in the National Institute of Hygiene and Epidemiology. She holds an MD from Hanoi Medical University, a Ph.D. in Epidemiology from the National Institute of Hygiene and Epidemiology, and completed post-doctoral training in emerging infectious diseases from the United States Center for Disease Control and Prevention in Atlanta.
Frank Malinoski Eveliqure Biotechnologies
CMOEveliqure Biotechnologiesオーストリア Dr. Malinouski has extensive, over twenty years of vaccine experience in preclinical, clinical, regulatory, medical affairs (post-licensure), safety, and business development, including board membership. He received a BA degree from Colby College in 1976 and trained in microbiology (Ph.D.; Rutgers University, 1981) and medicine (MD; Albany Medical College, 1985).
Throughout his career, he held numerous executive positions such as Director of Clinical Research at Lederle-Praxis Biologicals, Senior Vice President of Clinical and Medical Affairs at Nabi Biopharmaceuticals, Vice President of Medical Affairs at Wyeth, Chief Medical Officer, and Senior Vice President of Development for Oxxon Therapeutics, Inc, and Vice President and then Senior Vice President of Medical and Scientific Affairs at MedImmune, LLC. He served on the board of LigoCyte Pharmaceuticals, Inc., a biotech vaccine company in Bozeman, MT from March 2008 to March 2009 and is involved with the North Carolina Biotechnology Center in Wilmington, NC. Dr. Malinoski has authored or co-authored multiple scientific and vaccine-related publications and is a member of several editorial boards.
Daniel R. Vlock Alopexx
MD – Founder, CEOAlopexx
Dave E. Anderson VBI Vaccines
最高科学責任者VBI Vaccines米国A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. As a co-founder and Chief Scientific Officer of VBI, Dr. Anderson is an inventor of much of the Company’s intellectual property and actively manages its ongoing expansion. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California at Davis.
Ada Wong サノフィ
Asia Public Affairs Leadサノフィシンガポール
Per Fischer Minervax
CEO,Minervaxデンマーク Dr. Fischer is the CEO of MinervaX. has 25 years of experience in the biotech and pharmaceutical industry within product development and business development. He has founded and run several biotech companies, worked as a biotech consultant, and been an entrepreneur in residence with Novo Holdings. Primary therapeutic areas have been immunology, vaccines, hemostasis, and oncology. He holds a D.Phil. from the University of Oxford.
Kirill Dmitriev Russian Direct Investment Fund
最高経営責任者Russian Direct Investment Fundロシア Kirill Dmitriev heads the Russian Direct Investment Fund - one of the world's leading sovereign funds with a reserved capital of $10 billion under management. RDIF was established in 2011 on the initiative of the President and the Chairman of the Government of the Russian Federation. In all transactions, RDIF acts as a co-investor alongside major international investors, playing the role of a catalyst in attracting direct investment into Russia. RDIF has successfully invested with foreign partners in more than 90 projects totaling 2.1 trillion rubles and covering 95% of the regions of the Russian Federation. RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries totaling more than $40 billion.
Prior to becoming CEO of RDIF in 2011, Kirill Dmitriev headed a number of large private equity funds and completed a series of landmark transactions for Russia, including the sale of Delta Bank to General Electric, Delta Credit Bank to Société Générale, CTC Media to Fidelity Investments, among others. Mr. Dmitriev began his career at Goldman Sachs and McKinsey & Company.
He was appointed by the President of Russia as a member of the BRICS and APEC Business Councils. He serves as a member of the supervisory board of ALROSA, and of the boards of directors of Transneft, Rostelecom, Gazprombank, MDMG, Russian Railways , Rosseti and Skolkovo Foundation. Mr. Dmitriev is also on the boards of trustees of the Mariinsky Theatre, Lomonosov Moscow State University and National History Fund. He is Vice President of the Russian Union of Industrialists and Entrepreneurs.
S S Vasan CSIRO
Team LeaderCSIROオーストラリア
Luis Rios-Nogales ILiAD Biotechnologies
最高医療責任者ILiAD Biotechnologies米国
2021 スポンサーと出展者
ソリューションを紹介する アジアのトップワクチンエグゼクティブへ
ワクチン世界アジア会議2021は、あなたの製品について市場を教育し、主要な業界の人物と並んであなたの分野のリーダーとしての地位を確立する機会を提供します！これは、アジアのトップワクチンエグゼクティブの前にあなたのブランドとビジネスを位置付けるための特別な機会です。地域で最も人気のあるライフサイエンスサブセクターにアクセスできるようにしてください。
市場 知能
最新！電子書籍：治療および予防ワクチンパイプライン（アジア）
独占！ワクチン開発の課題-規制の視点
日本語 
English 
简体中文 
한국어 
繁體中文